All In Biotech

Drug Trial Radar · NCT07123727

A Study to Examine Anktiva for the Treatment of COVID-19.

Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Sep 4, 2025

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
Aug 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will examine the safety and effectiveness of Anktiva in treating patients with Long COVID-19 which is defined as persistent symptoms of a COVID-19 infection that remain after the infection is over.

Conditions

  • Long COVID
  • Long COVID Syndrome
  • Long Covid 19

Interventions

  • AnktivaDrug

    600ug of NAI administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment emergent adverse events (TEAEs) through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
  2. Incidence of grade 3 or higher TEAEs through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
  3. Incidence of serious adverse events (SAEs) through 30 days post final study drug administration.Time frame: Through 30 days post final study drug administration.
  4. Incidence of abnormal changes in safety laboratory tests (CBC and CMP).Time frame: Through the end of the study treatment period (approximately 75 days).
  5. Clinically important changes in vital signs such as temperature in degrees Fahrenheit.Time frame: Through the end of the study treatment period (approximately 75 days).
  6. Clinically important changes in vital signs such as heart rate in beats per minute.Time frame: Through the end of the study treatment period (approximately 75 days).
  7. Clinically important changes in vital signs such as blood pressure in millimeters of mercury (mmHg).Time frame: Through the end of the study treatment period (approximately 75 days).
  8. Clinically important changes in vital signs such as respiratory rate in breaths per minute.Time frame: Through the end of the study treatment period (approximately 75 days).
  9. Clinically important changes in vital signs such as oxygen saturation in percentage.Time frame: Through the end of the study treatment period (approximately 75 days).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chan Soon-Schiong Institute for Medicine (CSSIFM)

    El Segundo, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.